German health insurer CEO slams government for favoring pharma in cost-cutting talks
Jens Baas, CEO of Techniker Krankenkasse, has accused the German government of favouring the pharmaceutical industry in healthcare cost-cutting talks. Speaking during Bundestag negotiations, he argued that ministers are underestimating their own influence while overstating the power of drug manufacturers. Baas dismissed claims from the pharma lobby that drug pricing affects research and production choices. He pointed out that Germany already has the second-highest medication costs globally, trailing only the U.S. The industryâs warningâthat lower prices could lead to supply shortagesâwas also labelled implausible. As evidence, he cited the U.S. market, where no major corporation has withdrawn despite President Trumpâs past pressure on pricing.
He pushed for stricter savings measures from pharmaceutical firms, calling their current contributions insufficient. At the same time, he criticised the governmentâs proposal to cap salaries for insurance executives. According to Baas, health funds require skilled negotiators to challenge high drug prices effectively. The debate over reducing the number of insurance providers was another target of his criticism. Baas called it a political sideshow with minimal financial impact. He added that staff cuts at insurers were unrealistic, as most employees handle essential policyholder services.
Baasâs remarks highlight tensions between insurers and the government over healthcare savings. His arguments suggest that pharmaceutical companies, not insurers, should bear more responsibility for cost reductions. The outcome of these negotiations could shape future drug pricing and insurance operations in Germany.
